Open AccessASP2151 for the Treatment of Genital Herpes: A Randomized, Double-Blind, Placebo- and Valacyclovir-Controlled, Dose-Finding Study
Author(s) -
Stephen K. Tyring,
Anna Wald,
Neddie Zadeikis,
Shobha Dhadda,
Kazumasa Takenouchi,
Ramona Rorig
Publication year - 2012
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jis019
Subject(s) - medicine , placebo , adverse effect , randomized controlled trial , dose , herpes simplex virus , hazard ratio , clinical endpoint , incidence (geometry) , lesion , gastroenterology , surgery , immunology , virus , pathology , confidence interval , physics , alternative medicine , optics
Current therapies for genital herpes have only partial efficacy. Helicase-primase inhibitors are novel, potent inhibitors of herpes simplex virus replication.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom